The purpose of this study is to collect additional post-approval clinical data on the long-term performance of MemoryShape and MemoryGel Breast Implants, as indicated for primary or revisional breast augmentation and primary or revisional breast reconstruction.

开始日期2016-09-01

申办/合作机构

Mentor Worldwide LLC

NCT02724371 / Active, not recruitingN/A

A Study of the Safety and Effectiveness of the Mentor Smooth and Textured Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction

The study will evaluate the safety and effectiveness with the Mentor MemoryGel® Larger Size Ultra High Profile (UHP-L) Breast Implants.

开始日期2016-04-01

申办/合作机构

Mentor Worldwide LLC

NCT01225250 / CompletedN/AIIT

An Open-Label, Randomized, 2-Arm Parallel Study Comparing the Efficacy, Ease of Use, and Safety of PDS Plated Cartilagenous Grafting Versus Non-Plated Cartilagenous Grafting as Performed Through Endonasal Rhinoplasty

The purpose of this study is to determine efficacy, safety, and ease of cartilaginous grafting using polydioxanone (PDS) plates in comparison to non-plated cartilaginous grafts as performed through an endonasal rhinoplasty approach in patients requiring a caudal septal extension (CSE) graft.

开始日期2010-11-24

申办/合作机构

DeNova Research

[+1]

100 项与 Mentor Worldwide LLC 相关的临床结果

登录后查看更多信息

0 项与 Mentor Worldwide LLC 相关的专利（医药）

登录后查看更多信息

项与 Mentor Worldwide LLC 相关的文献（医药）

2017-12-01·Plastic and reconstructive surgery2区 · 医学

Mentor Contour Profile Gel Implants: Clinical Outcomes at 10 Years

2区 · 医学

Article

作者: Love, Tim R ; Wixtrom, Roger N ; Hammond, Dennis C ; Canady, John W ; Caplin, David A

Background::

Contour Profile Gel/MemoryShape breast implants consist of a textured silicone elastomer shell filled with silicone gel. The objective of this clinical study was to assess the safety and effectiveness of Contour Profile Gel/MemoryShape breast implants in women who were undergoing primary breast augmentation, primary breast reconstruction, or revision surgery (revision-augmentation or revision-reconstruction).

Methods::

This was a prospective, open-label, multicenter clinical study involving Contour Profile Gel/MemoryShape breast implants in 955 female subjects, including 572 primary augmentation, 124 revision-augmentation, 190 primary reconstruction, and 69 revision-reconstruction subjects. Safety was assessed based on the incidence, severity, and method of resolution of all complications. Endpoints were examined on both a per-subject and a per-implant basis.

Results::

For the primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction cohorts, the Kaplan-Meier estimated 10-year cumulative incidence rates for the key complications at the subject level were as follows: Baker grade III/IV capsular contracture, 3.6 (primary augmentation), 15.5 (revision-augmentation), 14.3 (primary reconstruction), and 16.4 (revision-reconstruction) percent; infection, 0.7 (primary augmentation), 1.9 (revision-augmentation), 1.6 (primary reconstruction), and 2.9 (revision-reconstruction) percent; explantation with or without replacement, 9.2 (primary augmentation), 25.9 (revision-augmentation), 34.1 (primary reconstruction), and 49.0 (revision-reconstruction) percent; explantation with replacement with study device, 4.0 (primary augmentation), 10.8 (revision-augmentation), 16.7 (primary reconstruction), and 27.9 (revision-reconstruction) percent; and any reoperation, 22.3 (primary augmentation), 35.0 (revision-augmentation), 52.7 (primary reconstruction), and 59.7 (revision-reconstruction) percent.

Conclusion::

The results of this study demonstrate that Contour Profile Gel/MemoryShape breast implants are safe and effective for primary and revision breast augmentation and reconstruction for women at least 22 years old.

2009-08-01·Cell transplantation3区 · 医学

Effects of Mechanical Stretch on Collagen and Cross-Linking in Engineered Blood Vessels

3区 · 医学

ArticleOA

作者: Dahl, Shannon L. M. ; Niklason, Laura E. ; Solan, Amy

It has been shown that mechanical stimulation affects the physical properties of multiple types of engineered tissues. However, the optimum regimen for applying cyclic radial stretch to engineered arteries is not well understood. To this end, the effect of mechanical stretch on the development of engineered blood vessels was analyzed in constructs grown from porcine vascular smooth muscle cells. Cyclic radial distension was applied during vessel culture at three rates: 0 beats per minute (bpm), 90 bpm, and 165 bpm. At the end of the 7-week culture period, harvested vessels were analyzed with respect to physical characteristics. Importantly, mechanical stretch at 165 bpm resulted in a significant increase in rupture strength in engineered constructs over nonstretched controls. Stress–strain data and maximal elastic moduli from vessels grown at the three stretch rates indicate enhanced physical properties with increasing pulse rate. In order to investigate the role of collagen cross-linking in the improved mechanical characteristics, collagen cross-link density was quantified by HPLC. Vessels grown with mechanical stretch had somewhat more collagen and higher burst pressures than nonpulsed control vessels. Pulsation did not increase collagen cross-link density. Thus, increased wall thickness and somewhat elevated collagen concentrations, but not collagen cross-link density, appeared to be responsible for increased burst strength.

2006-01-01·Journal of biomaterials science. Polymer edition3区 · 工程技术

Synthesis and characterization of a novel hyaluronic acid hydrogel

3区 · 工程技术

Article

作者: Zhao, X

Hyaluronic acid (hyaluronan, HA) has many medical applications as a biomaterial. To enhance its biostability, a novel hydrogel of cross-linked hyaluronic acid was prepared using a double cross-linking process, which involves building cross-linkages between hydroxyl group pairs and carboxyl group pairs. The present study explored a number of cross-linking processes in order to obtain different degrees of cross-linking, which were evaluated by the measurement of water absorption capacity as an index of the gel network density. To gain a better understanding of the stability of the gel, the chemical structure and particularly the rheological behaviour of the cross-linked HA, which included the influences of factors, such as degree of cross-linking, HA concentration and gel particle size, were investigated. The in vitro biostability against hyaluronidase and free radical degradation was tested to show that the cross-linked hydrogel had improved resistance to in vitro hyaluronidase and free radical degradation.

项与 Mentor Worldwide LLC 相关的新闻（医药）

2022-09-08

·PRNewswire

Susan G. Komen® Orange County MORE THAN PINK Walk Raises Money for Vital Breast Cancer Patient Services and Support

OC Community Support Needed for Patient Navigation and Screening and Diagnostics NEWPORT BEACH, Calif., Sept. 8, 2022 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, will hold an in-person OC MORE THAN PINK Walk to raise critical funds that support breast cancer patients in the community who are in need of direct patient services such as patient navigation and screening and diagnostics. The Komen OC MORE THAN PINK Walk will be held on Sunday, September 25, 2022, in Newport Beach at Pacific Life Insurance Company at Fashion Island. "We look forward to seeing our community that includes anyone impacted by breast cancer as we gather again, in person, for this year's OC MORE THAN PINK Walk. Funds raised support Komen's work in research and patient care services that are important to our community including patient navigation and screening and diagnostics," said Robin Walker, Development Director of OC Susan G. Komen. "For 30 years, Komen is a proud partner with our local OC community, and this year, our goal is to raise $550,000 to help people facing breast cancer today. With the economic downturn affecting those we serve, the demand for Komen services is greater than ever," said Walker. "We are grateful for everyone who is fundraising now, for our Walk Teams, sponsors and volunteers who make it possible for the women and men of OC facing breast cancer and metastatic breast cancer to receive the support they need." Komen appreciates our returning Walk sponsors: Pacific Life Insurance Company; Allergan Aesthetics, an AbbVie Company; Kaiser Permanente Orange County; Mentor Worldwide LLC; City of Newport Beach; Hoag Family Cancer Institute; Pepsi/Frito-Lay; UCI Health; KABC-TV; and Cox Communications. Komen is excited to welcome new sponsors for this year's OC Walk including Mother's Markets; Albertsons, Vons, Pavilions; Amgen; American Bone Health; Agendia; OC Fire Local 3631; Simplify Asset Management; Thales Avionics; Keck Medicine of USC Newport Beach; Breastlink/RadNet; and Ware Malcomb. Additionally, Brianna Ruffalo, KABC-TV meteorologist and reporter, will serve as Emcee of the OC Walk. Participants can expect to enjoy the following at the OC Walk: Complimentary breakfast for Top Fundraisers Free T-shirts for breast cancer survivors and MBC thrivers Pathway of Hope Parade honoring breast cancer survivors and MBC thrivers Hope Village where survivors and those living with MBC can gather Anaheim Ducks Mascot Wild Wing will make a special appearance thanks to Pacific Premiere Bank Participants can bring a photo to place with a special message to honor a loved one at the WE REMEMBER tent RESEARCH, CARE, COMMUNITY, AND ACTION tents for participants to see how their support makes a difference in OC Personalized back signs to share who serves as an inspiration to walk Local sponsors and vendors providing educational and resource information for patients and survivors DJ Desi to provide music Live marching band Komen OC MORE THAN PINK Walk Pacific Life Insurance Company at Fashion Island 700 Newport Center Dr., Newport Beach, CA 92660 Newport Beach, California Sunday, September 25, 2022 6 :30 AM Event Opens 8:30am Pathway of Hope Parade & Opening Ceremony 9:00 AM MORE THAN PINK Walk Begins Register Online for more information About Susan G. Komen® Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at . CONTACT: Deb Song (309)416-0419 [email protected] SOURCE Susan G. Komen for the Cure

2022-06-15

·PRNewswire

At 7.45% CAGR, Global Tissue Expander Market Size & Share to Surpass USD 1,236.78 Million by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research

NEW YORK, June 15, 2022 /PRNewswire/ -- As per Zion Market Research study, The global tissue expander market delivered revenue growth of USD 661.6 million in 2021 and is projected to expand at a CAGR of nearly 7.45 percent to reach USD 1,236.78 million by 2028. The report covers key driving elements along with the challenges and & restraints and their impact on the overall market expansion. The report also explores significant opportunities that could boost the market growth during the forecast period Key Industry Insights & Finding of the Tissue Expander Market Reports: As per the analysis shared by our research analyst, the Tissue Expander Market is expected to grow annually at a CAGR of around 7.45 % (2022-2028). Through the primary research, it was established that the Tissue Expander Market was valued approximately USD 661.6 Million in 2021 and is projected to reach to roughly USD 1,236.78 Million by 2028. North America tissue expander market held the highest share, accounting for 35 percent of the entire market. The rapid expansion of this region is due to the high prevalence of breast cancer, which has increased the use of foreskin restoration and tissue expanders in the North America region. The expansion of the tissue expander market in the region is being fueled by favorable government initiatives and an increasing number of research collaborations. Zion Market Research published the latest report titled as 'Tissue Expander Market By Shape (Anatomical, Round, Rectangular, Crescent, Others), Application (Breast Reconstruction, Forehead Skin & Scalp Reconstruction, Face & Neck Reconstruction, Others), End-Users (Hospitals, Cosmetology Clinics, Ambulatory Surgical Centers, Others), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028.' into their research database. Tissue Expander Market: Overview Tissue expanders are medical implants that are commonly utilized in cosmetic and trauma-related reconstructive operations. When these devices are implanted, they operate like a balloon that expands to stretch the tissue or skin covering the implant. Tissue expansion techniques including these implants are common in scalp reconstruction, breast reconstruction, and maxillofacial purposes. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 190 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Tissue Expander Market: Growth Drivers An upsurge in reconstruction surgeries across the world is expected to boost the market growth. One of the primary reasons driving the growth of the tissue expander market is the rise in the number of reconstructive procedures performed throughout the world. The rise in the prevalence of breast cancer, as well as the increased usage of tissue expanders in reconstruction operations such as scalp reduction surgery and reconstruction of the face, arms, neck, and legs, are driving market expansion. Further, the rise in the number of trauma incidents and serious car accidents, as well as the rising popularity of reconstructive surgeries like skin implants and skin grafting treatments, all have a positive impact on the market growth. In addition, the tissue expander industry benefits from lifestyle changes, increased healthcare spending, and increased public awareness of health issues. Tissue Expander Market: Restraints High costs allied with reconstruction surgeries may hamper the market growth. The high expenses linked with reconstruction procedures of breasts, face, and other body parts are among the major obstacles to the global tissue expander markets expansion. The high expense of breast reconstruction surgery in poor nations like South Africa is predicted to deter people from considering these procedures. The average breast reconstruction surgery costs between USD 3000 to USD 10,000. Furthermore, in developing countries, the average cost of a mastectomy is USD 4,500. Hormonal treatment, conventional chemotherapy, biological therapies, and radiation therapy are among the post-surgery procedures that cost between USD 5,500 to USD 30,000. Directly Purchase a Copy of the Report at Global Tissue Expander Market: Opportunities An increase in medical tourism is expected to support the market growth. In Asia Pacific and Latin American nations such as China, India, Japan, Brazil, Columbia, Costa Rica, and others, health or medical tourism is the current trend. Breast reconstruction is one of the most common operations performed in plastic surgery in these nations. The demand for plastic surgery is predicted to increase in these regions as a result of reduced treatment costs and an increase in the number of procedures done. In the following projected years, this is expected to support demand for tissue expanders by 25 percent of present levels. Global Tissue Expander Market: Challenges Prolonged tissue expander techniques and inadequate tissue expander supplies in underdeveloped economies pose a major challenge to market growth. The use of a tissue expander necessitates a more involved procedure. To be effective, the method necessitates a careful selection of the patient, meticulous preparation, and faultless execution. The operation typically lasts 8 to 12 weeks and requires two surgical sittings. Any compromise in this technique can lead to negative results and complexity, some of which are slight and allow the operation to continue in order to achieve the anticipated aim, while others are severe and result in the procedure being abandoned without achieving the intended goal. Furthermore, tissue expanders are in short supply in poor countries. Due to all such factors, the global tissue expander market expansion is being hampered. Global Tissue Expander Market: Segmentation The global tissue expander market is categorized based on shape, application, end-users, and region. Based on the shape, the market is bifurcated into round, anatomical, crescent, rectangular, and others. The applications of the market are segregated as face & neck reconstruction, breast reconstruction, forehead skin & scalp reconstruction, and others. By end-users, the market is bifurcated into hospitals, ambulatory surgical centers, cosmetology clinics, and others. Get More Insight before Buying at : List of Key Players of Tissue Expander Market: PMT Corporation ALLERGAN Mentor Worldwide LLC GC Aesthetics Sientra Inc. GROUPE SEBBIN SAS KOKEN CO.LTD. LABORATOIRES ARION POLYTECH Health & Aesthetics GmbH Wanhe Oxtex Ltd. Eurosurgical Ltd. Key questions answered in this report: What are the growth rate forecast and market size for Tissue Expander Market? What are the key driving factors propelling the Tissue Expander Market forward? What are the most important companies in the Tissue Expander Market Industry? What segments does the Tissue Expander Market cover? How can I receive a free copy of the Tissue Expander Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments: In Sept 2021, JOYTM, a revolutionary patient-centric breast aesthetics approach, has been announced by Establishment Labs Holdings Inc. Women who select JOY will get Establishment Labs' latest new-gen Motiva Ergonomix2® implants through a network of highly trained plastic surgeons and the sector's most comprehensive patient support program. JOY is being revealed at the 6th World Symposium on Ergonomic Implants, which is being held this week in Gardone Riviera, Italy, and is being addressed by over 200 plastic surgeons. In May 2021, Vizient, Inc. has awarded Sientra, Inc. with an Innovative Technology contract for their AlloX2 tissue expander. The contract went into force on May 1st, and it informs Vizient members about AlloX2's unique traits that might benefit the healthcare business. Vizient's Innovative Technology Program awards contracts based on the recommendations of healthcare specialists who serve on a Vizient member-led council that evaluates product applications. Regional Dominance: North America to dominate the global market during the forecast period. In 2021, North America tissue expander market held the highest share, accounting for 35 percent of the entire market. The rapid expansion of this region is due to the high prevalence of breast cancer, which has increased the use of foreskin restoration and tissue expanders in the region. Moreover, the expansion of the tissue expander market in the region is being fueled by favorable government initiatives and an increasing number of research collaborations. Furthermore, Asia Pacific region is expected to grow at the highest CAGR rate. This rapid increase in the market growth is due to variables such as an increase in the number of cases of trauma and catastrophic traffic accidents in nations such as India. Also, the increase in tissue inflammation is assumed to be the case in the nation. Moreover, the increasing cosmetics sector in emerging is fueling the tissue expander market's growth in Asia Pacific region. Global Tissue Expander Market is segmented as follows: Tissue Expander Market: By Shape Outlook (2022-2028) Anatomical Round Rectangular Crescent Others Tissue Expander Market: By Application Outlook (2022-2028) Breast Reconstruction Forehead Skin and Scalp Reconstruction Face and Neck Reconstruction Others Tissue Expander Market: By End Users Outlook (2022-2028) Hospitals Cosmetology Clinics Ambulatory Surgical Centers Others Tissue Expander Market: By Region Outlook (2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Press Release For Tissue Expander Market: Browse Other Related Research Reports from Zion Market Research Digital Patient Monitoring Devices Market - Global Industry Analysis : The global Digital Patient Monitoring Devices Market accrued earnings worth approximately 63.1 (USD Billion) in 2020 and is predicted to gain revenue of about 447.3(USD Billion) by 2028, is set to record a CAGR of nearly 24.1% over the period from 2021 to 2028. Viscosity Reducing Agents Market - Global Industry Analysis : The global Viscosity Reducing Agents Market accrued earnings worth approximately 10.1 (USD Billion) in 2020 and is predicted to gain revenue of about 19.2 (USD Billion) by 2028, is set to record a CAGR of nearly 5.1% over the period from 2021 to 2028. Leadless Pacemaker Systems Market - Global Industry Analysis : The global Leadless Pacemaker Systems Market accrued earnings worth approximately 55 (USD Million) in 2021 and is predicted to gain revenue of about 98 (USD Million) by 2028, is set to record a CAGR of nearly 10.1% over the period from 2022 to 2028. Browse through Zion Market Research's coverage of the Global Medical Device Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog - Logo: SOURCE Zion Market Research

放射疗法合作

2021-11-24

·新浪医药

受益于COVID-19药物和疫苗辉瑞明年收入有望突破1000亿_新浪医药新闻

编译丨李汤姆目前来看，COVID-19新冠肺炎疫情大流行正在创造一个价值1000亿美元的制药巨头。SVB Leerink分析师Geoffrey Porges在周一给客户的报告中预测，辉瑞在2022年的收入有望达到1013亿美元，主要贡献来自该公司与BioNTech合作的新冠肺炎疫苗和拥有出色临床数据的抗病毒疗法。这种收入水平在制药行业是闻所未闻的。强生2020年营收达到了826亿美元，成为全球收入最多的生物制药公司。据悉，辉瑞2018的收入为537亿美元，Porges估计，在1013亿美元的预期收入中，口服新冠肺炎药物Paxlovid可能会贡献242亿美元，新冠肺炎疫苗Comirnaty会带来297亿美元。根据辉瑞2021年的三季度财报显示，新冠疫苗Comirnaty第三季度销售总收入近130亿美元使得辉瑞将疫苗全年销售预测上调了7.5%，至360亿美元。辉瑞第三季度营收为241亿美元，超出市场预期。曾因仿制药等业务的剥离而收入大减的辉瑞看起来已经实现了蜕变，目前有重回全球药企榜首之势。辉瑞本月早些时候表示，在一项后期试验中，在新冠肺炎症状出现后三天内给予非住院患者Paxlovid治疗，试验结果显示与安慰剂相比，将新冠肺炎相关住院或死亡的风险降低了89%。该药物需要与HIV药物利托那韦联合使用。凭借积极的积极的试验数据，辉瑞正在寻求美国FDA对该药物的紧急使用授权。此前，美国政府已经决定以52.9亿美元购买了1000万疗程。Porges也承认，鉴于新冠肺炎大流行的不确定性，预测新冠肺炎产品的收入可能很困难。该分析师以2005至2007年期间围绕罗氏达菲等流感抗病毒药物的囤积行为做了参考。未来，中高收入国家将成为辉瑞新冠肺炎药物收入的主要贡献者。目前，该公司已与药品专利签署了许可协议，允许95个中低收入国家生产自己的Paxlovid版本。在辉瑞的主要目标市场，Porges预计政府将希望采购足够的库存来覆盖其10%至20%的人口，由于产能限制，这一采购需求在2022年或2023年不太可能得到满足。Porges指出，辉瑞预计2022年Paxlovid的产量为5000万疗程，然而整个库存需求约为2.22亿疗程。默沙东也推出了自己的口服新冠肺炎抗病毒药物，与Ridgeback Therapeutics合作的molnupiravir。在临床试验中，molnupiravir将患者住院或死亡的风险降低了约50%。拜登政府也已经签署了价值22亿美元的合同，购买了310万疗程的药物。除了新的新冠肺炎抗病毒市场机会之外，辉瑞已经通过Comirnaty获得了数百亿美元的收益。随着美国FDA为所有美国成年人授权注射疫苗，新冠肺炎疫苗又获得了另一笔收入增长。Porges预计，到2022年底，Comirnaty的累计销售额将达到1070亿美元，预计交付量将超过130亿剂。尽管Paxlovid已显示出更好的疗效数据，但Porges保守地预计50%的政府合同分配给辉瑞药物，还有在获得美国FDA全面批准后，该药物预计在商业市场上将占据70%份额。Porges表示，总体而言，在2024年之前的四年里，仅Paxlovid就可以为辉瑞带来671亿美元的累计销售额，季节性收入将从2023年开始。新冠肺炎疫苗和治疗药物提高辉瑞收入的同时，也为辉瑞的资产负债表上带来了一大笔现金。Porges估计，辉瑞的现金和有价证券总额将从9月底的297亿美元，增加到2022年底的595亿美元。如果葛兰素史克在2022年年中按计划成功剥离消费者健康合资企业，总额可能进一步增至761亿美元。Porges表示，辉瑞可以将这笔钱用于“战略目的”，暗示可能发生潜在的交易。参考来源：Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst *声明：本文由入驻新浪医药新闻作者撰写，观点仅代表作者本人，不代表新浪医药新闻立场。

疫苗合作紧急使用授权仿制药财报

100 项与 Mentor Worldwide LLC 相关的药物交易

登录后查看更多信息

100 项与 Mentor Worldwide LLC 相关的转化医学

登录后查看更多信息